Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Merrick

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Brachytherapy|April 6, 2004
Prostate brachytherapy in obese patientsJason Rockhill, Kent Wallner, Cory Hoffman, et al.
American Journal of Clinical Oncology|June 6, 2008
The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cureNathan Bittner, Kent Wallner, Gregory Merrick, et al.
Medical Physics|May 30, 2003
Interpretation of pre- versus postimplant TRUS imagesStephen Smith, Kent Wallner, Gregory Merrick, et al.
The Journal of Urology|September 18, 2007
Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinomaRizwan Nurani, Kent Wallner, Gregory Merrick, et al.
Medical Physics|May 30, 2003
Prostate brachytherapy seed identification on post-implant TRUS imagesBen H Han, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleedingAmy Mueller, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Clinical correlates of high intraprostatic brachytherapy dose volumesShaleah Jones, Kent Wallner, Gregory Merrick, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2004
The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapyTracy Sherertz, Kent Wallner, Gregory Merrick, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 10, 2005
20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trialKent Wallner, Gregory Merrick, Lawrence True, et al.
American Journal of Clinical Oncology|April 1, 2008
There is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapyAndrew Herstein, Kent Wallner, Gregory Merrick, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Brachytherapy|April 6, 2004
Prostate brachytherapy in obese patientsJason Rockhill, Kent Wallner, Cory Hoffman, et al.
American Journal of Clinical Oncology|June 6, 2008
The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cureNathan Bittner, Kent Wallner, Gregory Merrick, et al.
Medical Physics|May 30, 2003
Interpretation of pre- versus postimplant TRUS imagesStephen Smith, Kent Wallner, Gregory Merrick, et al.
The Journal of Urology|September 18, 2007
Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinomaRizwan Nurani, Kent Wallner, Gregory Merrick, et al.
Medical Physics|May 30, 2003
Prostate brachytherapy seed identification on post-implant TRUS imagesBen H Han, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleedingAmy Mueller, Kent Wallner, Gregory Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Clinical correlates of high intraprostatic brachytherapy dose volumesShaleah Jones, Kent Wallner, Gregory Merrick, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2004
The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapyTracy Sherertz, Kent Wallner, Gregory Merrick, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 10, 2005
20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trialKent Wallner, Gregory Merrick, Lawrence True, et al.
American Journal of Clinical Oncology|April 1, 2008
There is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapyAndrew Herstein, Kent Wallner, Gregory Merrick, et al.
Pageof 5